middle.news
Lumos Diagnostics Secures US$317M Deal as FebriDx Nears FDA Milestone
9:06am on Monday 21st of July, 2025 AEST
•
Healthcare
Read Story
Lumos Diagnostics Secures US$317M Deal as FebriDx Nears FDA Milestone
9:06am on Monday 21st of July, 2025 AEST
Key Points
FY25 revenue rose 12% to US$12.4 million
Q4 revenue declined 26% due to end of U.S. flu season
Exclusive US distribution deal with PHASE Scientific valued at US$317 million
FebriDx CLIA waiver study nearing completion with FDA application expected soon
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics Holdings (ASX:LDX)
OPEN ARTICLE